Wednesday, October 19, 2005

OncoLink coverage of the Annual Meeting of the American Society for Therapeutic Radiology And Oncology, ASTRO, October 16-20, 2005, held in Denver, Colorado. OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.

OncoLink's new booth

A Phase I-II Study of COX-2 Inhibitor, Celebrex (Celecoxib) and Chemoradiation in Patients With Locally Advanced Cervical Cancer: Primary Endpoint Analysis of RTOG 0128 Presenter: Presenter: D.K.GaffneyPresenter's Affiliation: Radiation Oncology, University of Utah, Salt Lake City, UT, Statistics, RTOG, Philadelphia, PA, Radiation Oncology, Thomas Jefferson Univ., Philadelphia, PA, Obstetrics/Gynecology, Wake Forest...
Clinical Application of Positron Emission Tomography (PET) in Designing Radiation Fields in Non-Small Cell Lung Cancer (NSCLC) Patients Presenter: Charles G. Wood, MDPresenter's Affiliation: University of Pennsylvania, Dept. of Radiation Oncology, Philadelphia, PAType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both...
Exclusive High-Dose Rate Brachytherapy (HDR-BT) for Limited Non-small Cell Lung Carcinoma: Results of a French Study in 199 Patients Presenter: M.A. MahePresenter's Affiliation: Radiotherapy, Centre Oscar Lambret, Lille, FranceType of Session: ScientificBackground The standard of care for treatment of early stage lung cancer is surgery with or without chemotherapy. HDR-BT is an...
Hypofractionated Intensity Modulated Radiotherapy (70 Gy at 2.5Gy Per Fraction) for Localized Prostate Cancer: Long-Term Outcome Results Presenter: V.V. ThakkarPresenter's Affiliation: Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OHType of Session: ScientificBackground The principle of α /β has always been instrumental in guiding radiation...
Impact of Computed Tomography and 18F-Deoxyglucose-Hybrid Positron Emission Tomography Image Fusion on Conformal Radiotherapy in Non-Small Cell Lung Cancer Presenter: E. Deniaud-Alexandre.Presenter's Affiliation: Tenon Hospital, Paris, FranceType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans...
Initial Report of a Prospective Phase II Trial of Stereotactic Body Radiation Therapy for Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer Presenter: R. TimmermanPresenter's Affiliation: UT-Southwestern Medical CenterType of Session: ScientificBackground Patients with medically inoperable stage I non-small cell lung cancer are potentially amenable to stereotactic body radiation therapy...
Integrity of Parotid Gland Delineation for H&N IMRT: What are we sparing? Presenter: T.S. HongPresenter's Affiliation: Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, Department of Medical Physics, University of Wisconsin Medical School, Madison, WI, Department of Radiology, UniversiType...
Is Anemia a Cause of Radiation Treatment Failure in Patients with Squamous Carcinoma of the Cervix? Presenter: P.J. EifelPresenter's Affiliation: Department of Radiation Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, Gynecologic OncologyType of Session: ScientificBackground Previous studies have shown that anemia is an independent...
Preliminary Analysis of RTOG 9902: Increased Toxicity Observed with the Use of Adjuvant Chemotherapy Presenter: H.M. SandlerPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: ScientificBackground The current standard of care for patients with high risk prostate cancer includes local radiotherapy in conjunction with...
Subcutaneous (SbQ) Versus Intravenous (IV) Administration of Amifostine for Head and Neck (HN) Cancer Patients Receiving Radiotherapy (RT): Preliminary Results of the GORTEC 2000-02 Randomized Trial Presenter: E. BardetPresenter's Affiliation: Crlcc, Nantes, FranceType of Session: ScientificBackground There are several advantages offered by SbQ amifostine over IV amifostine including easier administration and a favorable window between drug...
Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC). Presenter: J. E. Bekelman, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground In 1998, the PORT meta-analysis of nine clinical trials (2128 patients) concluded that when compared to...